Get the Daily Brief
Latest Biotech News
Thermo Fisher upgrades mass‑spec and acquires Clario in data‑driven push
Thermo Fisher Scientific unveiled the Orbitrap Astral Zoom MS—an instrument that raises throughput and sensitivity for proteomics and metabolomics studies—and concurrently moved to deepen clinical...
AI accelerates drug discovery — open models and big‑tech breakthroughs
Academic groups and startups continue to push AI into core drug‑discovery tasks: MIT and Recursion released Boltz‑2 for rapid binding‑affinity prediction, and SandboxAQ and others are advancing...
Nanoparticle IL‑12 strategies revive ovarian cancer immunotherapy in preclinical models
MIT and collaborating teams reported polymer‑coated nanoparticles and other nanomaterials that deliver IL‑12 directly to ovarian tumor sites, enhancing responses to immune‑checkpoint inhibitors...
Metsera takeover battle: Pfizer sues, Novo counters with bigger bid
Pfizer filed a Delaware court suit accusing Novo Nordisk of improperly disrupting its agreed acquisition of obesity biotech Metsera and seeking a temporary restraining order. Pfizer alleges Novo’s...
FDA halts Intellia’s CRISPR trials after liver safety signals
The US Food and Drug Administration placed a clinical hold on Intellia’s two Phase 3 studies of nexiguran ziclumeran (nex‑z), a CRISPR-based in vivo gene‑editing candidate for transthyretin...
Synthetic biology scales: industry adopts engineering and AI tools
Biopharma companies are integrating synthetic biology to design novel modalities, optimize production and reach previously intractable targets. Companies like Mammoth Biosciences and others are...
From bench to one‑off cures: Baby KJ pushes FDA pathway for bespoke gene therapy
Researchers behind the bespoke CRISPR therapy for 'Baby KJ' published detailed FDA interactions and are engaging regulators to formalize a pathway for bespoke gene‑editing treatments. The team...
Organoids meet xenotransplantation: scalable human kidney organoids grafted in pigs
Researchers reported a scalable method to produce thousands of human kidney organoids and demonstrated their integration into porcine kidneys using ex vivo normothermic perfusion. Teams infused...
AI proposes drugs: Google model and open tools speed discovery
Google’s Cell2Sentence‑Scale foundation model (27B parameters) reportedly proposed and validated a cancer drug combination, marking an AI‑driven step in hypothesis generation for oncology....
Commercial push for heritable genome editing draws scrutiny
A new US company, Preventive, announced significant private funding to research heritable genome editing with the stated goal of assessing safety and responsible practice for editing embryos. The...
CAR‑T: clinical gains clash with commercial headwinds
A comparative study showed axicabtagene ciloleucel (axi‑cel) outperformed conventional first‑line therapy for high‑risk large B‑cell lymphoma, reinforcing clinical momentum for CAR‑T in earlier...
Mass‑spec scales multiomics: instruments boost throughput and depth
Mass spectrometry vendors pushed new hardware and workflows—such as the Orbitrap Astral Zoom MS—raising throughput to hundreds of samples per day and improving depth to measure ~8,000 proteins per...
Regulatory pivot: FDA signals deregulatory moves as key PDUFAs loom
FDA Commissioner signaled forthcoming 'deregulatory' actions following the agency’s relaxation of some biosimilar trial requirements, indicating further shifts imminently. Separately, industry...
Metsera M&A fight erupts: Pfizer sues as Novo tops bid
Pfizer moved to block Novo Nordisk’s unsolicited takeover attempt for obesity biotech Metsera after Novo lodged a higher bid, escalating a high‑stakes M&A battle in the obesity drug market. Pfizer...
FDA halts Intellia’s CRISPR trials – liver safety alarm
The FDA placed a formal clinical hold on two Phase 3 studies of Intellia Therapeutics’ CRISPR editing candidate nexiguran ziclumeran (nex‑z) after a severe liver adverse event prompted the company...
UCL–UCLA gene therapy posts milestone: durable ADA‑SCID cures reported
A collaborative UCL and UCLA gene therapy program reported durable immune reconstitution in children with ADA‑SCID, achieving reported success rates near 95% with no long‑term safety signals in...
Human kidney organoids scaled and grafted into porcine kidneys
Researchers developed a scalable, reproducible method to produce thousands of human kidney organoids and demonstrated integration of those organoids into perfused porcine kidneys ex vivo. The...
AI accelerates discovery…models and infrastructure scale up
Two developments point to AI’s expanding role in drug discovery: academic and industry groups released Boltz‑2, an AI model that predicts small‑molecule binding affinity at speed, and the Chan...
CAR‑T market jitters: sales slip even as axi‑cel shows clinical promise
Commercial dynamics for cell therapies are shifting: Gilead reported an 11% drop in cell‑therapy revenue for the quarter, citing lower demand for Yescarta and Tecartus, while a separate clinical...
Thermo Fisher to buy Clario for $8.88B – clinical data play
Thermo Fisher Scientific agreed to acquire Clario Holdings for $8.88 billion in cash to bolster its clinical data and endpoint capabilities. The deal—announced by Thermo Fisher—adds Clario’s...